A Phase 2 interventional study of Semaglutide (SEMA) and Cilofexor (CILO)/Firsocostat (FIR) in Nonalcoholic Steatohepatitis, sponsored by Gilead Sciences. Completed at 242 sites in 7 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-11-26.
Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease — 4 open to participants now, 8 under way, 1 of them phase 3. Semaglutide · Non-alcoholic Fatty Liver Disease.
Among the 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease, this one is the 2nd largest by enrollment, is one of 4 that started in 2021, is one of 8 in phase 2, and was the 9th registered.
1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →4 of the 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease are open now, in 3 countries. Recruiting first, the newest first:
University of Virginia · Sites in United States
Ages 18–75
Dr Adnan Agha · Sites in United Arab Emirates
Ages 18–99
RenJi Hospital · Sites in China
Ages 18–65
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Sites in United States
Ages 18–100 · Healthy volunteers
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 10 · Phase 3 2 · Phase 4 3
First in 2016; this study’s year is marked. 4 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 457 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 88 across the 16 interventional studies. Of the 8 that completed or were terminated, 5 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 16 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences: none open now, none under way, none of them phase 3. Of 16 finished, 15 (94%) have results posted.
Among the 16 studies in Non-alcoholic Fatty Liver Disease by Gilead Sciences, this one is the 3rd largest by enrollment, is the only one that started in 2021, is one of 11 in phase 2, and was the 16th registered.
Gilead Sciences’s Non-alcoholic Fatty Liver Disease studies by the year they started, since 2008.
3 of the studies testing semaglutide in Non-alcoholic Fatty Liver Disease that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05195944University Health Network, TorontoSemaglutide vs Sitagliptin | 2026-12 |
| NCT05067621Yale UniversitySemaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Metabolic Dysfunction-Associated Steatotic Liver Disease | 2026-12 |
| NCT06005012University of California, San DiegoSemaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM | 2026-12-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies testing semaglutide in Non-alcoholic Fatty Liver Disease, from their registry updates:
Among Gilead Sciences’s 16 in Non-alcoholic Fatty Liver Disease:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The goal of this clinical study is to understand whether the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due to NASH.
Key Inclusion Criteria:
Screening laboratory parameters as determined by the study central laboratory:
Key Exclusion Criteria:
Men who habitually drink greater than 21 units/week of alcohol or women who habitually drink greater than 14 units/week of alcohol (1 unit is equivalent to 12 ounce (oz)/360 mL of beer, a 4 oz/120 mL glass of wine, or 1 oz/30 mL of hard liquor).
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive semaglutide (SEMA) 3.0 mg/mL, once weekly and cilofexor and firsocostat (CILO/FIR) 30 mg/20 mg fixed-dose combination (FDC) tablet, once daily up to 72 weeks.
Drug: Semaglutide (SEMA) · Drug: Cilofexor (CILO)/Firsocostat (FIR)
Participants will receive SEMA 3.0 mg/mL, once weekly and Placebo-To-Match (PTM) CILO/FIR FDC tablet, once daily up to 72 weeks.
Drug: Semaglutide (SEMA) · Drug: PTM CILO/FIR
Participants will receive PTM SEMA, once weekly and CILO/FIR 30 mg/20 mg FDC tablet, once daily up to 72 weeks.
Drug: Cilofexor (CILO)/Firsocostat (FIR) · Drug: PTM SEMA
Participants will receive PTM SEMA, once weekly and PTM CILO/FIR FDC tablet, once daily up to 72 weeks.
Drug: PTM SEMA · Drug: PTM CILO/FIR
Administered as subcutaneous (SC) injection
Drug pages: Cilofexor · Firsocostat
Tablets administered orally
Also known as: GS-9674/GS-0976
Administered as SC injection
Tablets administered orally
Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) + Cilofexor/Firsocostat (CILO/FIR) Fixed Dose Combination (FDC) Versus Placebo Groups
Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH clinical research network (CRN) classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.
Time frame: Week 72
Percentage of Participants Who Achieved ≥1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 72 in SEMA + CILO/FIR FDC Versus SEMA Alone
Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH CRN classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.
Time frame: Week 72
Percentage of Participants With NASH Resolution Without Worsening in Fibrosis at Week 72 in SEMA + CILO/FIR FDC Versus Placebo Groups
NASH resolution is defined as lobular inflammation of 0 or 1 and hepatocellular ballooning of 0. Worsening in fibrosis was defined as a change in fibrosis worsening stage as per NASH CRN criteria. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.
Time frame: Week 72
Percentage of Participants With NASH Resolution Without Worsening in Fibrosis In Participants Treated With SEMA + CILO/FIR FDC Versus CILO/FIR Alone Groups
NASH resolution is defined as lobular inflammation of 0 or 1 and hepatocellular ballooning of 0. Worsening in fibrosis was defined as a change in fibrosis worsening stage as per NASH CRN criteria. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.
Time frame: Week 72
Participants were enrolled at study sites in the United States, Canada, France, Japan, Australia and Spain.
| Milestone | SEMA + CILO/FIR FDC | SEMA + PTM CILO/FIR | PTM SEMA + CILO/FIR FDC | PTM SEMA + PTM CILO/FIR |
|---|---|---|---|---|
| Started | 125 | 124 | 123 | 85 |
| Completed | 103 | 104 | 91 | 65 |
| Not completed | 22 | 20 | 32 | 20 |
| Withdrew: Withdrew consent | 5 | 5 | 17 | 7 |
| Withdrew: Adverse event | 7 | 8 | 6 | 3 |
| Withdrew: Lost to follow-up | 2 | 1 | 6 | 7 |
| Withdrew: Protocol violation | 3 | 1 | 1 | 2 |
| Withdrew: Investigator's discretion | 3 | 1 | 1 | 0 |
| Withdrew: Randomized but never treated | 1 | 2 | 0 | 1 |
| Withdrew: Death | 0 | 1 | 1 | 0 |
| Withdrew: Site terminated by sponsor | 1 | 1 | 0 | 0 |
Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH clinical research network (CRN) classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.
| percentage of participants | SEMA + CILO/FIR FDC | PTM SEMA + PTM CILO/FIR |
|---|---|---|
| Percentage of Participants Who Achieved ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 72 in Semaglutide (SEMA) + Cilofexor/Firsocostat (CILO/FIR) Fixed Dose Combination (FDC) Versus Placebo Groups | 13.7 (8.2 to 21.0) | 8.3 (3.4 to 16.4) |
Fibrosis improvement was defined as ≥ 1-stage decrease from baseline in fibrosis according to the NASH CRN classification. Worsening of NASH was defined as ≥ 1-point increase from baseline in hepatocellular ballooning or lobular inflammation. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.
| percentage of participants | SEMA + CILO/FIR FDC | SEMA + PTM CILO/FIR |
|---|---|---|
| Percentage of Participants Who Achieved ≥1-Stage Improvement in Fibrosis Without Worsening of NASH at Week 72 in SEMA + CILO/FIR FDC Versus SEMA Alone | 13.7 (8.2 to 21.0) | 15.6 (9.6 to 23.2) |
NASH resolution is defined as lobular inflammation of 0 or 1 and hepatocellular ballooning of 0. Worsening in fibrosis was defined as a change in fibrosis worsening stage as per NASH CRN criteria. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.
| percentage of participants | SEMA + CILO/FIR FDC | PTM SEMA + PTM CILO/FIR |
|---|---|---|
| Percentage of Participants With NASH Resolution Without Worsening in Fibrosis at Week 72 in SEMA + CILO/FIR FDC Versus Placebo Groups | 57.3 (45.9 to 68.2) | 22.4 (11.8 to 36.6) |
NASH resolution is defined as lobular inflammation of 0 or 1 and hepatocellular ballooning of 0. Worsening in fibrosis was defined as a change in fibrosis worsening stage as per NASH CRN criteria. Clopper-Pearson method was used in outcome measure analysis in each arm. Percentages were rounded-off.
| percentage of participants | SEMA + CILO/FIR FDC | PTM SEMA + CILO/FIR FDC |
|---|---|---|
| Percentage of Participants With NASH Resolution Without Worsening in Fibrosis In Participants Treated With SEMA + CILO/FIR FDC Versus CILO/FIR Alone Groups | 57.3 (45.9 to 68.2) | 31.8 (22.3 to 42.6) |
Collected over All-cause mortality and Adverse events: Up to 72 weeks plus 35 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SEMA + CILO/FIR FDC | 0/125 (0%) | 17/124 (13.7%) | 101/124 (81.5%) |
| SEMA + PTM CILO/FIR | 1/124 (0.8%) | 13/122 (10.7%) | 97/122 (79.5%) |
| PTM SEMA + CILO/FIR FDC | 1/123 (0.8%) | 18/123 (14.6%) | 85/123 (69.1%) |
| PTM SEMA + PTM CILO/FIR | 0/85 (0%) | 11/84 (13.1%) | 60/84 (71.4%) |
| Event | SEMA + CILO/FIR FDC | SEMA + PTM CILO/FIR | PTM SEMA + CILO/FIR FDC | PTM SEMA + PTM CILO/FIR |
|---|---|---|---|---|
| Hepatocellular carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/124 | 0/122 | 3/123 | 1/84 |
| NephrolithiasisRenal and urinary disorders | 3/124 | 0/122 | 0/123 | 1/84 |
| Acute kidney injuryRenal and urinary disorders | 1/124 | 2/122 | 0/123 | 1/84 |
| Covid-19 pneumoniaInfections and infestations | 0/124 | 0/122 | 2/123 | 0/84 |
| AscitesGastrointestinal disorders | 0/124 | 0/122 | 0/123 | 1/84 |
| Prosthetic cardiac valve stenosisGeneral disorders | 0/124 | 0/122 | 0/123 | 1/84 |
| Diverticulitis intestinal perforatedInfections and infestations | 0/124 | 0/122 | 0/123 | 1/84 |
| SepsisInfections and infestations | 0/124 | 0/122 | 1/123 | 1/84 |
| Hip fractureInjury, poisoning and procedural complications | 0/124 | 0/122 | 0/123 | 1/84 |
| HyponatraemiaMetabolism and nutrition disorders | 0/124 | 0/122 | 0/123 | 1/84 |
| Event | SEMA + CILO/FIR FDC | SEMA + PTM CILO/FIR | PTM SEMA + CILO/FIR FDC | PTM SEMA + PTM CILO/FIR |
|---|---|---|---|---|
| NauseaGastrointestinal disorders | 59/124 | 49/122 | 29/123 | 19/84 |
| DiarrhoeaGastrointestinal disorders | 34/124 | 25/122 | 16/123 | 15/84 |
| ConstipationGastrointestinal disorders | 30/124 | 26/122 | 11/123 | 7/84 |
| VomitingGastrointestinal disorders | 27/124 | 21/122 | 7/123 | 6/84 |
| Covid-19Infections and infestations | 21/124 | 15/122 | 15/123 | 14/84 |
| Decreased appetiteMetabolism and nutrition disorders | 19/124 | 20/122 | 7/123 | 5/84 |
| FatigueGeneral disorders | 17/124 | 17/122 | 9/123 | 11/84 |
| Abdominal painGastrointestinal disorders | 11/124 | 10/122 | 6/123 | 11/84 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 8/124 | 6/122 | 12/123 | 11/84 |
| HypoglycaemiaMetabolism and nutrition disorders | 14/124 | 4/122 | 3/123 | 5/84 |
The Safety Analysis Set included all participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | SEMA + CILO/FIR FDC | SEMA + PTM CILO/FIR | PTM SEMA + CILO/FIR FDC | PTM SEMA + PTM CILO/FIR | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 72 | 73 | 67 | 44 | 256 |
| >=65 years | 52 | 49 | 56 | 40 | 197 |
| Age, Continuous(years) | SEMA + CILO/FIR FDC | SEMA + PTM CILO/FIR | PTM SEMA + CILO/FIR FDC | PTM SEMA + PTM CILO/FIR | Total |
|---|---|---|---|---|---|
| Mean | 61 ± 10.4 | 61 ± 9.2 | 62 ± 9.5 | 63 ± 9.1 | 62 ± 9.6 |
| Sex: Female, Male(Participants) | SEMA + CILO/FIR FDC | SEMA + PTM CILO/FIR | PTM SEMA + CILO/FIR FDC | PTM SEMA + PTM CILO/FIR | Total |
|---|---|---|---|---|---|
| Female | 83 | 85 | 74 | 50 | 292 |
| Male | 41 | 37 | 49 | 34 | 161 |
| Ethnicity (NIH/OMB)(Participants) | SEMA + CILO/FIR FDC | SEMA + PTM CILO/FIR | PTM SEMA + CILO/FIR FDC | PTM SEMA + PTM CILO/FIR | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 28 | 23 | 30 | 19 | 100 |
| Not Hispanic or Latino | 95 | 99 | 90 | 62 | 346 |
| Unknown or Not Reported | 1 | 0 | 3 | 3 | 7 |
| Race (NIH/OMB)(Participants) | SEMA + CILO/FIR FDC | SEMA + PTM CILO/FIR | PTM SEMA + CILO/FIR FDC | PTM SEMA + PTM CILO/FIR | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 3 | 1 | 1 | 2 | 7 |
| Asian | 11 | 9 | 15 | 3 | 38 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 2 | 1 | 1 | 5 | 9 |
| White | 100 | 108 | 98 | 66 | 372 |
| More than one race | 5 | 2 | 3 | 4 | 14 |
| Unknown or Not Reported | 3 | 1 | 5 | 4 | 13 |
| Region of Enrollment(Participants) | SEMA + CILO/FIR FDC | SEMA + PTM CILO/FIR | PTM SEMA + CILO/FIR FDC | PTM SEMA + PTM CILO/FIR | Total |
|---|---|---|---|---|---|
| United States | 95 | 99 | 88 | 63 | 345 |
| Canada | 7 | 7 | 12 | 6 | 32 |
| France | 5 | 5 | 9 | 10 | 29 |
| Japan | 4 | 6 | 6 | 1 | 17 |
| Australia | 6 | 2 | 6 | 2 | 16 |
| Spain | 7 | 3 | 2 | 2 | 14 |
Showing the first 100 of 242 sites across 7 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2021 to primary completion in Nov 2024, 39 months.
Results were first posted in Nov 2025, 1 year after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 39 months is above that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Semaglutide · Cilofexor · Firsocostat
Non-alcoholic Fatty Liver Disease →